1-151002246-T-G
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001376665.1(MINDY1):āc.372A>Cā(p.Glu124Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000812 in 1,614,200 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Consequence
NM_001376665.1 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MINDY1 | NM_001376665.1 | c.372A>C | p.Glu124Asp | missense_variant | 2/10 | ENST00000683666.2 | NP_001363594.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MINDY1 | ENST00000683666.2 | c.372A>C | p.Glu124Asp | missense_variant | 2/10 | NM_001376665.1 | ENSP00000507359 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152190Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.000151 AC: 38AN: 251458Hom.: 0 AF XY: 0.000221 AC XY: 30AN XY: 135900
GnomAD4 exome AF: 0.0000855 AC: 125AN: 1461892Hom.: 1 Cov.: 30 AF XY: 0.000135 AC XY: 98AN XY: 727246
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152308Hom.: 0 Cov.: 31 AF XY: 0.0000806 AC XY: 6AN XY: 74474
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 02, 2024 | The c.516A>C (p.E172D) alteration is located in exon 3 (coding exon 2) of the FAM63A gene. This alteration results from a A to C substitution at nucleotide position 516, causing the glutamic acid (E) at amino acid position 172 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at